These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 11049019)

  • 1. Manipulation of the stem cell as a target for hematologic malignancies.
    Ballen KK; Becker PS; Stewart FM; Quesenberry PJ
    Semin Oncol; 2000 Oct; 27(5):512-23. PubMed ID: 11049019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplant as a platform for tumor immunotherapy.
    Fuchs EJ; Whartenby KA
    Curr Opin Mol Ther; 2004 Feb; 6(1):48-53. PubMed ID: 15011781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
    Handgretinger R; Kurtzberg J; Egeler RM
    Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome.
    Yüksel M; Baron E; Camouse M; Cooper BW; Lazarus HM; Gerson SL; Laughlin MJ; Cooper KD; Gilliam A; Fu P; Stevens S; Koç ON
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):665-71. PubMed ID: 16737940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into cord blood stem cell transplantation.
    Tse W; Bunting KD; Laughlin MJ
    Curr Opin Hematol; 2008 Jul; 15(4):279-84. PubMed ID: 18536563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to treating malignances with stem cell transplantation.
    Margolis J; Borrello I; Flinn IW
    Semin Oncol; 2000 Oct; 27(5):524-30. PubMed ID: 11049020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
    Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
    Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
    di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A
    Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation in hematologic malignancy.
    Archuleta TD; Devetten MP; Armitage JO
    Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches.
    Friedman TM; Varadi G; Hopely DD; Filicko J; Wagner J; Ferber A; Martinez J; Brunner J; Grosso D; McGuire L; Korngold R; Flomenberg N
    Biol Blood Marrow Transplant; 2001; 7(12):656-64. PubMed ID: 11787528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies.
    Kanda J; Ichinohe T; Matsuo K; Benjamin RJ; Klumpp TR; Rozman P; Blumberg N; Mehta J; Sohn SK; Uchiyama T
    Transfusion; 2009 Apr; 49(4):624-35. PubMed ID: 19170998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.